Autonomix Medical (AMIX) Financials

Autonomix Medical remains a pre-revenue company with persistent operating losses, although its latest quarter showed modest improvement in spending and cash usage. Revenue was reported at zero in each provided income statement, meaning the company is still funding research and development without product sales to offset expenses.

• Quarterly net loss improved in Q4 2026. The net loss narrowed to $2.7 million from $3.3 million in Q3 and $7.5 million in Q2. Operating expenses also declined to $2.7 million, compared with $3.3 million in Q3 and $7.5 million in Q2.
• Cash operating burn has moderated. Net cash used in operating activities declined to $2.9 million in Q4 2026 from $3.0 million in Q3 and $3.8 million in Q2. This was also relatively close to the $2.5 million quarterly burn reported in Q4 2025.
• The balance sheet remains lightly leveraged. At December 31, 2025, Autonomix reported $1.7 million of total liabilities, no noncurrent debt and $8.6 million of equity. Current assets of $10.2 million substantially exceeded current liabilities of $1.7 million.
• Investment income provides a small offset to operating losses. Interest and investment income ranged from $70,000 to $84,000 in the 2026 quarters, supported by the company’s cash holdings.
• Cash levels have been supported primarily by equity financing. Autonomix raised $6.0 million through common equity issuance in Q3 2026, following $2.1 million in Q1 and $386,000 in Q2. This financing has helped fund operations but does not represent internally generated cash.
• Capital spending is minimal. Property and equipment purchases were only $3,000 in Q4 2026, and net property, plant and equipment was $20,000 at the latest reported balance-sheet date. This suggests the company has limited capital-intensive infrastructure at this stage.
• Autonomix has not yet demonstrated revenue generation. Every provided income statement reported zero revenue and zero gross profit, leaving the company dependent on outside capital while it develops its medical technology.
• The company continues to report significant losses and negative operating income. Q4 2026 operating income was negative $2.7 million, while retained earnings were negative $64.4 million at December 31, 2025, reflecting substantial cumulative losses.
• Cash declined materially in Q4. Net cash decreased by $2.9 million during the quarter, compared with a $2.5 million decline in Q1 and a $1.1 million decline in Q2. Based on the December 31 cash balance of $9.9 million, the Q4 cash flow would imply approximately $7.0 million of cash afterward, although a Q4 balance sheet was not provided.
• Future dilution remains a major risk. The company’s financing history shows repeated reliance on common-stock issuance, while weighted-average basic shares increased from 3.1 million in Q1 2026 to 7.2 million in Q4. Additional fundraising could further dilute existing shareholders.

Overall, the financial statements show a company with adequate near-term liquidity relative to its current liabilities but no operating revenue and a continuing cash burn. At the recent quarterly operating burn of roughly $2.9 million, the December cash balance would cover only a limited number of quarters without additional financing. Investors should closely monitor clinical or commercial progress, quarterly spending, cash balances and any future equity offerings.